title: Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
abstract: Relapse of acute promyelocytic leukemia (APL) following all-trans retinoic acid (ATRA) therapy has been associated with the acquisition of mutations in the high-affinity ATRA binding site in PML-RARalpha, but little information is available about the selection dynamics of the mutation-harboring subclones. In this study, 6/18 patients treated with sequential ATRA and chemotherapy on protocol INT0129 relapsed with complete replacement of the nonmutant pretreatment APL cell population by a PML-RARalpha mutant subclone. Two patients relapsed in proximity of ATRA treatment; however, in four patients there was a 6-48 month hiatus between the last ATRA treatment and relapse. The mutant subclones were not detectable in samples tested > or = 3 months before relapse at > or = 1 in 10(2) (10(-2)) sensitivity. In one patient, a functionally weak mutation was detected at 10(-4) sensitivity before therapy but only limited pre-relapse enrichment of the mutant subclone was observed on subsequent ATRA therapy. These results indicate that proximate ATRA selection pressure is frequently not the main determinant for the emergence of strongly dominant PML-RARalpha mutant subclones and suggest that APL subclones harboring PML-RARalpha mutations are predisposed to the acquisition of secondary genetic/epigenetic alterations that result in a growth/survival advantage.
authors.affiliation: Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA. rgallagh@aecom.yu.edu
authors.forename: R E
authors.initials: RE
authors.lastname: Gallagher
authors.forename: E L
authors.initials: EL
authors.lastname: Schachter-Tokarz
authors.forename: D-C
authors.initials: DC
authors.lastname: Zhou
authors.forename: W
authors.initials: W
authors.lastname: Ding
authors.forename: S H
authors.initials: SH
authors.lastname: Kim
authors.forename: B J
authors.initials: BJ
authors.lastname: Sankoorikal
authors.forename: W
authors.initials: W
authors.lastname: Bi
authors.forename: K J
authors.initials: KJ
authors.lastname: Livak
authors.forename: J L
authors.initials: JL
authors.lastname: Slack
authors.forename: C L
authors.initials: CL
authors.lastname: Willman
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001665:Binding Sites; D019070:Cell Lineage; D002999:Clone Cells; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D044127:Epigenesis, Genetic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D009363:Neoplasm Proteins / Q000187:drug effects / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000187:drug effects / Q000235:genetics*; D012008:Recurrence; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D013329:Structure-Activity Relationship; D014212:Tretinoin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin